Meet Our Management Team

Together, they are furthering NuView Life Science’s mission: to change the way many types of cancer are diagnosed and treated using precision medicine technology. Diagnosing and treating cancer with a targeted, specific approach to the disease will help to increase positive patient outcomes while also driving down costs incurred by patients, healthcare providers, and third-party insurance payers.

PAUL J. CROWE

Chairman and CEO

Mr. Crowe founded NuView Life Sciences in 2005 and serves as its Chairman and Chief Executive Officer. Mr. Crowe’s experience includes start-up and early-stage healthcare company development, strategic planning, capital formation, M&A, and public offerings. Mr. Crowe’s career includes senior executive sales and management positions for domestic and multi-national healthcare companies who introduced (a) diagnostic ultrasound in 1973 for Rohe Ultrasound – NV Philips Medical Systems; (b) nuclear magnetic resonance (NMR / MRI) in 1983 for Diasonics NMR Inc.; and (c) mobile positron emission tomography (PET) in 1999 for Mobile P.E.T. Systems Inc., Between 1986 and 1999 Mr. Crowe developed and operated outpatient medical service provider businesses, including diagnostic imaging facilities and gamma knife radio surgery facilities, and currently serves on the Board of Radiosurgical Centers of San Diego located at Scripps Memorial Hospital.

STEPHANE ALLARD, MD

Chief Medical Officer

Dr. Allard, M.D. serves as our Chief Medical Officer. Dr. Allard also served in executive positions at Sanofi-Synthelabo, Synthelabo, Inc. and Lorex Pharmaceuticals. Dr. Allard received his medical doctorate from Rouen Medical College and received a Diplomate of CESAM (Certificate of Statistical Studies Applied to Medicine) and a PhD in Clinical Pharmacology and Pharmacokinetics (Pitie Salpetriere Hospital); Paris, France. Medical Officer 35 years of pharmaceutical industry experience, and President of Synthelabo. Dr Allard was previously US VP of Medical Affairs at Sanofi and Chief Medical Officer of EpiCept/Immune Pharmaceuticals. He led development for Ambien and Eloxatin and was responsible for European approval of Ceplene.

THOMAS BROWN

Chief Financial Officer

Mr. Brown has over 40 years of business and financial experience in the analysis, structuring and sourcing of capital, valuation, repositioning/restructuring and the management of financial/operating assets as well as businesses. Mr. Brown is the founding partner of three investment banking firms, a private equity firm and an investment management firm. Mr. Brown has served as the CFO of several public and private companies as well as non-profit organizations focused on coordinating the reporting and management of the financial infrastructure of emerging growth ventures and organizations. In addition to serving on the board of several public, private and non-profit organizations, Mr. Brown has been the chairman of the audit committees of several public companies. Mr. Brown graduated from the University of Southern California with a B.S. in Finance and earned the Chartered Financial Analyst (CFA) designation.

MARK WILLIG

Vice President of Business Development

Mr. Willig has developed and executed upon global commercial, market access, and business strategies for over thirty years for companies ranging from leading start-ups to Fortune 500 life science companies. Mr. Willig was responsible for the launch of genetic and genomic testing at four different start-ups including Myriad, where under his leadership revenue grew to thirty million dollars with a CAGR of 200%, PrognostiX which became the Cleveland Heat Lab and was acquired by Quest Diagnostics, Agendia which grew to thirty million dollars and CardioDx with revenue growth from seven million to thirty-seven million dollars. At all four organizations, Mr. Willig was responsible for gaining positive medical policy and contracting with the first commercial payers. Mr. Willig also served as the global commercial leader for a $280 million-dollar business unit at Thermo Fisher Scientific. Most recently Mr. Willig was the Founder and Principal of Blue Ocean Consulting, LLC where he worked with many early-stage life science organizations providing them with their go-to-market, commercial, market access and business development strategies for their initial product offering.

Jill Helmke, D.Ph,N.Ph.

Special Projects Manager

Jill S. Helmke, Certified Nuclear Pharmacist and Doctor of Pharmacy, comes to NuView Life Sciences, with over 25 years of pharmacy experience ranging from outpatient pharmacy to clinical research. A graduate of The Ohio State University, she also completed a specialty in Nuclear Medicine. In addition, she has degrees in Business Management and Music from Baldwin Wallace University. Dr. Helmke practiced nuclear medicine for 15 years at Cardinal Health and Vanderbilt University Medical Center, specializing in Positron Emission Tomography (PET). While at Vanderbilt, she branched into Biomedical Informatics wherein she focused on pediatric drug formulations, as well as compounding research and development. A major contributor to STEPStools (Safety through Electronic Prescribing System Tools), Dr. Helmke presented her research to the American Academy of Pediatrics in Washington D.C. and has received national recognition for her efforts in Biomedical Informatics. After relocating to Park City, UT, Dr. Helmke continued her Biomedical Informatics research with the University of Utah. Subsequently, she conducted Phase I-IV clinical drug trials with PRA Health Sciences.

STEVEN J. DAVIS

General Counsel

Mr. Davis is the founder of SD Law Group, a corporate and securities law firm located in San Diego, California, which was founded in 2005.

Mr. Davis has worked with a wide variety of clients in the areas of corporate, securities and business law since 1992 and has been responsible for over $1 billion in transactions. He is also on the Board of Directors of Theragene Pharmaceuticals, Inc. and Philter Labs, Inc., and was on the Board of Directors and Audit, Compensation, Nominating Committees (Chairman) and Special Committee (Chairman) of Telanetix, Inc., a publicly traded telecommunications company which was sold to InterMedia (an Oak Hill Capital portfolio company). He served as General Counsel and an executive officer of Molecular Imaging Corporation, a publicly traded healthcare company, and as in-house counsel for Leap Wireless International, a publicly traded wireless carrier. He also practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP (now Dentons), a large full-service law firm, where he advised both private and public clients in a variety of transactions.

Mr. Davis is licensed to practice law in California, the District of Columbia, and Minnesota. He received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law in 1992. He received his B.A. in Political Science, Cum Laude, from Arizona State University in 1988.

He has also co-founded Clonatec, one of the first French biotech companies.